Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias

经导管左心耳封堵术与抗凝治疗对患有心房颤动、阿尔茨海默病及相关痴呆症的老年人的有效性和安全性

基本信息

  • 批准号:
    10672458
  • 负责人:
  • 金额:
    $ 70.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary Non-valvular atrial fibrillation (AF) is highly prevalent in older adults and associated with a 5-fold increased risk of cardioembolic stroke. Oral anticoagulants (OACs) can reduce this risk by ~70%, but nearly 50% of such older patients are not anticoagulated, with Alzheimer’s disease and related dementias (ADRD) being among the leading cited reasons, attributed to a higher risk of falls, medication errors, and poor adherence. Since the vast majority of thrombus formation in AF occurs in the left atrial appendage, transcatheter left atrial appendage occlusion (LAAO) has been approved in the US since 2015 as a one-time procedural alternative treatment for stroke prevention in AF patients with high risks of complications from OACs. The uptake of transcatheter LAAO has been growing at a rate of 2 to 3-fold yearly, and it is clearly changing the prescribing pattern of OACs in AF patients. However, our pilot data showed persons living with dementia (PLWDs) are significantly less likely to receive transcatheter LAAO when it is indicated. One likely barrier is that PLWDs and frail older adults were much under-represented in the randomized controlled trials (RCTs) which led to transcatheter LAAO approval. Also, several high-risk characteristics prevalent in PLWDs, including frailty, dementia severity, fall risks, and advanced kidney disease, are risk factors for both the transcatheter LAAO procedure-related complications and bleeding risks from OACs, complicating the prescribing decisions. Thus, there is an urgent need to investigate the net clinical benefit, weighing the benefits of stroke prevention against the major bleeding and procedure complications, comparing transcatheter LAAO with specific OACs in PLWDs. Our objective is to establish a prospective monitoring program in 3 large national healthcare utilization databases (Medicare, IBM Marketscan, and Optum claims data, covering ~15 million lives) from 2015-2025, linked to electronic health records (EHR). We will evaluate treatment outcomes of transcatheter LAAO vs. specific OACs in PLWDs with AF with detailed treatment effect heterogeneity evaluation by frailty, dementia severity, fall risks, advanced kidney disease, and patient-reported and family factors. We will also determine the utilization trends, predictors, and barriers of transcatheter LAAO and OACs in PLWDs, using a novel signal detection tool, TreeScan, developed by the applicant team and adopted by the US Food and Drug Administration for prospective drug safety monitoring. Our central hypothesis is that transcatheter LAAO has a favorable long-term net clinical benefit compared with OACs in PLWDs and the relative benefits vary by specific identifiable clinical factors. This proposal will yield: 1) direct benefit-to-risk data to inform the use of transcatheter LAAO and specific OACs for stroke prevention in PLWDs with AF; 2) a novel and generalizable prospective monitoring program that compares effectiveness and safety of newly marketed medical devices vs. pharmacotherapies in PLWDs with detailed treatment effect heterogeneity evaluation.
项目摘要 非瓣膜性心房颤动(房颤)在老年人中非常普遍,并与增加5倍的风险有关 心脏栓塞性中风。口服抗凝剂(OAC)可以将这种风险降低约70%,但近50%的老年人 患者没有抗凝,阿尔茨海默病和相关痴呆(ADRD)是 主要列举的原因,归因于较高的跌倒风险、用药失误和依从性差。既然广袤无边 房颤时血栓形成多发生在左心耳、经导管左心耳 自2015年以来,闭塞术(LAAO)已在美国获得批准,作为一种一次性的程序性替代治疗方法 房颤患者OAC并发症高危人群的卒中预防。经导管对LAAO的摄取 以每年2到3倍的速度增长,显然正在改变房颤患者OAC的处方模式 病人。然而,我们的试点数据显示,痴呆症患者(PLWD)患痴呆症的可能性显著降低 在需要时接受经导管LAAO治疗。一个可能的障碍是PLWD和虚弱的老年人 在导致经导管LAAO批准的随机对照试验(RCT)中,该研究的代表性很低。 此外,PLWD中普遍存在的几个高危特征,包括虚弱、痴呆症严重程度、跌倒风险和 晚期肾脏疾病是经导管LAAO手术相关并发症和 OAC的出血风险,使处方决策复杂化。因此,迫切需要进行调查。 净临床收益,权衡卒中预防与大出血和手术的益处 并发症,比较经导管LAAO和特定OAC在PLWDS中的应用。我们的目标是建立一个 3个大型国家医疗保健利用数据库(Medicare、IBM MarketScan、 与电子健康记录(EHR)相关联的2015年至2025年的Optus索赔数据(涵盖约1500万人的生命)。 我们将评估经导管LAAO与特异性OAC在伴有房颤的PLWDS中的治疗结果。 通过虚弱、痴呆症严重程度、跌倒风险、晚期肾脏疾病和 患者报告的因素和家庭因素。我们还将确定以下各项的利用率趋势、预测因素和障碍 经导管LAAO和OAC在PLWD中的应用,使用由The 申请者团队,并被美国食品和药物管理局采用,用于预期的药物安全监测。 我们的中心假设是,与经导管LAAO相比,经导管LAAO具有良好的长期净临床益处 OAC在PLWD中的应用及其相对益处因特定的可识别的临床因素而异。这项建议将产生:1) 直接的风险效益数据,为使用经导管LAAO和特定的OAC预防中风提供信息 2)一个新的和可推广的前瞻性监测计划,将有效性和 具有详细治疗效果的PLWD中新上市医疗器械的安全性与药物疗法的比较 异质性评价。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSHUA K LIN其他文献

JOSHUA K LIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSHUA K LIN', 18)}}的其他基金

A targeted analytical framework to optimize posthospitalization delirium pharmacotherapy in patients with Alzheimers disease and related dementias
优化阿尔茨海默病和相关痴呆患者出院后谵妄药物治疗的有针对性的分析框架
  • 批准号:
    10634940
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Deprescribing antipsychotics in patients with Alzheimers disease and related dementias and behavioral disturbance in skilled nursing facilities
在熟练护理机构中取消阿尔茨海默病及相关痴呆症和行为障碍患者的抗精神病药物处方
  • 批准号:
    10634934
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Effectiveness and Safety of Transcatheter Left Atrial Appendage Occlusion vs. Anticoagulation in Older Adults with Atrial Fibrillation and Alzheimer's Disease and Related dementias
经导管左心耳封堵术与抗凝治疗对患有心房颤动、阿尔茨海默病及相关痴呆症的老年人的有效性和安全性
  • 批准号:
    10443345
  • 财政年份:
    2022
  • 资助金额:
    $ 70.97万
  • 项目类别:
Developing scalable algorithms to incorporate unstructured electronic health records for causal inference based on real-world data
开发可扩展的算法以合并非结构化电子健康记录,以基于真实世界数据进行因果推断
  • 批准号:
    10372142
  • 财政年份:
    2020
  • 资助金额:
    $ 70.97万
  • 项目类别:
Developing scalable algorithms to incorporate unstructured electronic health records for causal inference based on real-world data
开发可扩展的算法以合并非结构化电子健康记录,以基于真实世界数据进行因果推断
  • 批准号:
    10581591
  • 财政年份:
    2020
  • 资助金额:
    $ 70.97万
  • 项目类别:
Developing dynamic prognostic and risk-stratification models for informing prescribing decisions in older adults with Coronavirus Disease 2019
开发动态预后和风险分层模型,为患有 2019 年冠状病毒病的老年人的处方决策提供信息
  • 批准号:
    10189838
  • 财政年份:
    2019
  • 资助金额:
    $ 70.97万
  • 项目类别:
Improving comparative effectiveness research through electronic health records continuity cohorts
通过电子健康记录连续性队列改进比较有效性研究
  • 批准号:
    9983157
  • 财政年份:
    2017
  • 资助金额:
    $ 70.97万
  • 项目类别:
Improving comparative effectiveness research through electronic health records continuity cohorts
通过电子健康记录连续性队列改进比较有效性研究
  • 批准号:
    9766389
  • 财政年份:
    2017
  • 资助金额:
    $ 70.97万
  • 项目类别:
Improving comparative effectiveness research through electronic health records continuity cohorts
通过电子健康记录连续性队列改进比较有效性研究
  • 批准号:
    9365420
  • 财政年份:
    2017
  • 资助金额:
    $ 70.97万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 70.97万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了